Commonwealth Equity Services LLC Raises Stake in Integra Lifesciences Holdings Corp (IART)

Commonwealth Equity Services LLC lifted its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 8.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,913 shares of the life sciences company’s stock after purchasing an additional 965 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Integra Lifesciences were worth $784,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of IART. Los Angeles Capital Management & Equity Research Inc. grew its stake in Integra Lifesciences by 26.0% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 9,348 shares of the life sciences company’s stock valued at $616,000 after purchasing an additional 1,930 shares during the period. First National Bank of Omaha grew its stake in Integra Lifesciences by 2.8% in the 3rd quarter. First National Bank of Omaha now owns 39,980 shares of the life sciences company’s stock valued at $2,633,000 after purchasing an additional 1,076 shares during the period. Zions Bancorporation bought a new position in Integra Lifesciences in the 3rd quarter valued at $272,000. Victory Capital Management Inc. bought a new position in Integra Lifesciences in the 3rd quarter valued at $4,155,000. Finally, State Board of Administration of Florida Retirement System grew its stake in Integra Lifesciences by 2.2% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 73,754 shares of the life sciences company’s stock valued at $4,858,000 after purchasing an additional 1,579 shares during the period. 85.94% of the stock is currently owned by institutional investors.

A number of brokerages have issued reports on IART. UBS Group began coverage on Integra Lifesciences in a research note on Tuesday, November 27th. They issued a “neutral” rating and a $58.00 price objective for the company. Zacks Investment Research downgraded Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Monday, November 26th. Citigroup reduced their price objective on Integra Lifesciences from $66.00 to $60.00 and set a “neutral” rating for the company in a research note on Friday, November 2nd. JMP Securities cut their price target on Integra Lifesciences from $66.00 to $62.00 and set a “market outperform” rating for the company in a research note on Friday, November 2nd. Finally, Wells Fargo & Co cut their price target on Integra Lifesciences from $61.00 to $55.00 and set a “market perform” rating for the company in a research note on Thursday, November 1st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $61.62.

IART stock opened at $53.78 on Tuesday. The company has a quick ratio of 2.08, a current ratio of 3.20 and a debt-to-equity ratio of 1.04. The firm has a market cap of $4.57 billion, a PE ratio of 27.72, a PEG ratio of 1.67 and a beta of 0.76. Integra Lifesciences Holdings Corp has a fifty-two week low of $45.96 and a fifty-two week high of $67.50.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, hitting the consensus estimate of $0.59. The company had revenue of $365.85 million during the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.45 EPS. On average, equities analysts forecast that Integra Lifesciences Holdings Corp will post 2.39 EPS for the current year.

In related news, Director Barbara B. Hill acquired 3,705 shares of the company’s stock in a transaction that occurred on Monday, November 5th. The shares were acquired at an average price of $53.90 per share, with a total value of $199,699.50. Following the acquisition, the director now owns 63,381 shares of the company’s stock, valued at approximately $3,416,235.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of the stock in a transaction dated Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total value of $2,949,456.44. Following the sale, the insider now directly owns 134,134 shares in the company, valued at approximately $8,475,927.46. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Commonwealth Equity Services LLC Raises Stake in Integra Lifesciences Holdings Corp (IART)” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/12/04/commonwealth-equity-services-llc-raises-stake-in-integra-lifesciences-holdings-corp-iart.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: Diversification

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit